CALCITRIOL-ODAN CAPSULE
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
03-10-2014
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
CALCITRIOL
可用日期:
ODAN LABORATORIES LTD
ATC代码:
A11CC04
INN（国际名称）:
CALCITRIOL
剂量:
0.25MCG
药物剂型:
CAPSULE
组成:
CALCITRIOL 0.25MCG
给药途径:
ORAL
每包单位数:
30/100
处方类型:
Prescription
治疗领域:
VITAMIN D
產品總結:
Active ingredient group (AIG) number: 0113628007; AHFS:
授权状态:
APPROVED
授权日期:
2014-09-24
产品特点
PRODUCT MONOGRAPH
PR CALCITRIOL-ODAN
TM
Calcitriol
Capsules 0.25 mcg and 0.5 mcg
House standard VITAMIN D
3 METABOLITE
ODAN LABORATORIES LTD.
DATE OF PREPARATION:
325 STILLVIEW AVENUE
SEPTEMBER 23, 2014
POINTE-CLAIRE, QC
CANADA H9R 2Y6
Submission Control No: 161455
CALCITRIOL-ODAN
TM
is a trade-mark of Odan Laboratories Limited.
_Page 1 of 25_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
..................................................................................................3
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
...................................................................................................5
DRUG INTERACTIONS
...................................................................................................7
DOSAGE AND ADMINISTRATION
...............................................................................8
OVERDOSAGE
...............................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
...........................................................11
STORAGE AND STABILITY
.........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................12
PART II: SCIENTIFIC INFORMATION
..............................................................................14
PHARMACEUTICAL INFORMATION
.........................................................................14
CLINICAL TRIALS
.........................................................................................................14
DETAILED PHARMACOLOGY
.......................
阅读完整的文件
